Clinical Trial

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

MOA: Camizestrant is an oral selective estrogen receptor degrader (SERD)

Key Eligibility Criteria:

• ER+ (>10%)/HER2-negative early-stage invasive BC with no evidence of metastatic disease
• Pts must meet criteria for high or intermediate-high risk of recurrence
• Completed breast surgery +/- radiotherapy, +/- (neo)adj chemo
• Pts must be randomized w/in 12 weeks after RT or last dose of chemotherapy. Pts may have received up to 12 weeks of ET in (neo)adjuvant setting prior to randomization
• Pts may have received abemaciclib up to 12 weeks prior to randomization
• Pts with pCR or RCB-0 after neoadjuvant chemo are excluded
• Pts must be randomized within 12 months of breast surgery